These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 10809991)

  • 21. TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression.
    Asakura K; Uchida H; Miyachi H; Kobayashi H; Miyakawa Y; Nimer SD; Takahashi H; Ikeda Y; Kizaki M
    Mol Cancer Res; 2004 Jun; 2(6):339-47. PubMed ID: 15235109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
    Efferth T; Sauerbrey A; Steinbach D; Gebhart E; Drexler HG; Miyachi H; Chitambar CR; Becker CM; Zintl F; Humeny A
    Int J Oncol; 2003 Aug; 23(2):509-17. PubMed ID: 12851703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug resistance: molecular and clinical aspects.
    Dicato M; Duhem C; Pauly M; Ries F
    Cytokines Cell Mol Ther; 1997 Jun; 3(2):91-9. PubMed ID: 9287248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity.
    Ahn HK; Jang JH; Kim K; Kim HJ; Kim SH; Jung CW; Kim DH
    Am J Hematol; 2012 Jan; 87(1):37-41. PubMed ID: 22120708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistance (MDR) genes in haematological malignancies.
    Nooter K; Sonneveld P
    Cytotechnology; 1993; 12(1-3):213-30. PubMed ID: 7765326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].
    Machaczka M; Rucińska M; Jabłoński M; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):407-13. PubMed ID: 10021886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppressors and reversion of multidrug-resistance.
    Aouali N; Eddabra L; Macadré J; Morjani H
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):61-70. PubMed ID: 15978826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-glycoprotein (P-170) expression in acute leukemias.
    Abd El-Ghaffar HA; Aladle DA; Farahat SE; Abd El-Hady N
    Hematology; 2006 Feb; 11(1):35-41. PubMed ID: 16522547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multidrug resistance in hematological malignancies: prognostic significance and the effect of resistance-modulating drugs].
    Sonneveld P; te Boekhorst PA
    Ned Tijdschr Geneeskd; 1994 Mar; 138(10):508-12. PubMed ID: 7908127
    [No Abstract]   [Full Text] [Related]  

  • 30. MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients.
    Mahjoubi F; Akbari S; Montazeri M; Moshyri F
    Genet Mol Res; 2008; 7(4):1369-74. PubMed ID: 19065772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma.
    Solary E; Bidan JM; Calvo F; Chauffert B; Caillot D; Mugneret F; Gauville C; Tsuruo T; Carli PM; Guy H
    Leukemia; 1991 Jul; 5(7):592-7. PubMed ID: 1677057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classical multidrug resistance in acute myeloid leukaemia.
    Paietta E
    Med Oncol; 1997 Mar; 14(1):53-60. PubMed ID: 9232613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis.
    Doxani C; Voulgarelis M; Zintzaras E
    Biomarkers; 2013 Aug; 18(5):425-35. PubMed ID: 23805980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Detection of multidrug resistance in patients with leukemia by using flow cytometry and RNA in situ hybridization].
    Li S; Wang C; Yao C
    Zhonghua Nei Ke Za Zhi; 1996 Sep; 35(9):591-4. PubMed ID: 9592351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The relationship between abnormal MDR gene expression and chemotherapy response in lymphoid malignancies].
    Xu YC; Lin YM; Zhang FC
    Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):353-6. PubMed ID: 17044999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of multidrug resistance in multiple myeloma.
    Sonneveld P
    Baillieres Clin Haematol; 1995 Dec; 8(4):831-44. PubMed ID: 8845575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multidrug or pleiotropic resistance].
    Arvelo F; Merentes E; Cotte C
    Acta Cient Venez; 2000; 51(1):45-52. PubMed ID: 10974707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of the MDR1 and MRP genes in patients with lymphoma with primary bone marrow involvement.
    Zenkov AN; Scvortsova NV; Chernolovskaya EL; Pospelova TI; Vlassov VV
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(6-7):843-7. PubMed ID: 15560070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of P-glycoprotein expression in haematological malignancies.
    Nooter K; Sonneveld P
    Leuk Res; 1994 Apr; 18(4):233-43. PubMed ID: 7909572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma cell P170 expression and response to treatment in multiple myeloma.
    Patriarca F; Melli C; Damiani D; Michieli M; Michelutti A; Cavo M; Baccarani M
    Haematologica; 1996; 81(3):232-7. PubMed ID: 8767528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.